MDR-001 achieved statistically significant weight reductions of 8.2% to 10.3% at 24 weeks compared to 2.5% with placebo ...

Novo Nordisk launches Wegovy in India, a once-weekly weight-loss injection shown to aid obesity treatment and reduce heart ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

The drug works by acting on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, ...

人気の高いGLP-1受容体作動薬「オゼンピック」とは異なる仕組みで作用する、実験的な肥満治療薬が開発されている。人間を対象とした小規模な予備的試験では、体重減少に効果を示す可能性が確認された。

Danish drugmaker Novo Nordisk has fast-tracked the India launch of its blockbuster anti-obesity drug Wegovy (semaglutide 2.4 ...

Danish pharmaceutical giant Novo Nordisk on Tuesday announced the launch of its anti-obesity drug Wegovy in India, targeting ...

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Obesity caused by a high-fat Western diet damages the pancreas, affecting insulin production and blood sugar control even ...

On June 19, 2025 The Globe and Mail hosted an event where experts discussed how treating obesity as a chronic disease can ...